Difference between revisions of "ERF for short term PM10 exposure and medication usage by people with asthma"
From Testiwiki
Line 4: | Line 4: | ||
[[Category: PM exposure health effects]] | [[Category: PM exposure health effects]] | ||
− | |||
== Scope == | == Scope == | ||
− | + | ||
− | |||
− | |||
Exposure-response function for short-term (acute) exposure to ambient air particulate matter (PM) with an aerodynamic diameter < 10 µm and medication (bronchodilator) usage by people with asthma. | Exposure-response function for short-term (acute) exposure to ambient air particulate matter (PM) with an aerodynamic diameter < 10 µm and medication (bronchodilator) usage by people with asthma. | ||
Line 22: | Line 19: | ||
=== Data === | === Data === | ||
− | |||
− | |||
− | |||
− | |||
'''''WHO task group (2004) <ref>[http://www.euro.who.int/document/E82792.pdf Anderson, H.R., Atkinson, R.W., Peacock, J.L., Marston, L. & Konstantinou, K. 2004. Meta-analysis of time-series studies and panel studies of Particulate Matter (PM) and Ozone (O3) - Report of a WHO task group. World Health Organization.]</ref> | '''''WHO task group (2004) <ref>[http://www.euro.who.int/document/E82792.pdf Anderson, H.R., Atkinson, R.W., Peacock, J.L., Marston, L. & Konstantinou, K. 2004. Meta-analysis of time-series studies and panel studies of Particulate Matter (PM) and Ozone (O3) - Report of a WHO task group. World Health Organization.]</ref> | ||
Line 42: | Line 35: | ||
=== Causality === | === Causality === | ||
− | |||
− | |||
− | |||
=== Unit === | === Unit === | ||
− | + | ||
Annual change in no. of days of bronchodilator usage per 10 µg/m3 increase in exposure per 1000 persons | Annual change in no. of days of bronchodilator usage per 10 µg/m3 increase in exposure per 1000 persons | ||
Line 54: | Line 44: | ||
=== Formula === | === Formula === | ||
− | |||
− | |||
== Result == | == Result == | ||
− | + | ||
{|{{prettytable}} | {|{{prettytable}} | ||
Line 78: | Line 66: | ||
==See also== | ==See also== | ||
− | + | ||
*[http://www.needs-project.org/docs/results/RS1b/NEEDS_Rs1b_D3.7.pdf NEEDS - New Energy Externalities Developments for Sustainability, Deliverable 3.7 "A set of concentration-response function", Integrated Project, Sixth Framework Programme, Project no. 502687.] | *[http://www.needs-project.org/docs/results/RS1b/NEEDS_Rs1b_D3.7.pdf NEEDS - New Energy Externalities Developments for Sustainability, Deliverable 3.7 "A set of concentration-response function", Integrated Project, Sixth Framework Programme, Project no. 502687.] | ||
Line 84: | Line 72: | ||
==References== | ==References== | ||
− | + | ||
− | |||
<references/> | <references/> |
Latest revision as of 10:11, 18 November 2009
This page is a variable.
The page identifier is Op_en3443 |
---|
Moderator:Virpi Kollanus (see all) |
Give your opinion to the peer rating of the content of this page. |
Upload data
|
Contents
Scope
Exposure-response function for short-term (acute) exposure to ambient air particulate matter (PM) with an aerodynamic diameter < 10 µm and medication (bronchodilator) usage by people with asthma.
Dimensions and boundaries relevant for the variable
- Age of exposed population
- Country/other geographic area
Definition
Data
WHO task group (2004) [1]
- RR of 1.005 (95% Cl 0.981, 1.029) for bronchodilator usage by children with asthma (meeting PEACE study criteria) per 10 µg/m3 PM10
- RR of 1.010 (95% Cl 0.990, 1.031) for bronchodilator usage by adults with asthma (well-established) per 10 µg/m3 PM10
Note! the associations are not statistically significant at the usual 5% level.
CAFE CBA (2005)[2]
- Annual change of 180 (95% Cl -690, 1060) days in brochodilator usage per 10 µg/m3 PM10 per 1000 children aged 5-14 years with asthma (meeting PEACE study criteria)
- Based on the RR by WHO task group (2004) and 10% background prevalence of daily bronchodilator use
- Annual change of 912 (95% Cl -912, 2774) days in brochodilator usage per 10 µg/m3 PM10 per 1000 adults aged 20+ with well-established asthma with asthma (well-established)
- Based on the RR by WHO task group (2004) and 50% background prevalence of daily bronchodilator use
- 4.5% of European adult population was estimated to have well-established asthma
Causality
Unit
Annual change in no. of days of bronchodilator usage per 10 µg/m3 increase in exposure per 1000 persons
Formula
Result
Age group | Days | 95% Cl |
---|---|---|
5-14 | 180 | -690, 1060 |
20+ | 912 | -912, 2774 |
|}
See also
References
- ↑ Anderson, H.R., Atkinson, R.W., Peacock, J.L., Marston, L. & Konstantinou, K. 2004. Meta-analysis of time-series studies and panel studies of Particulate Matter (PM) and Ozone (O3) - Report of a WHO task group. World Health Organization.
- ↑ Service Contract for Carrying out Cost-Benefit Analysis of Air Quality Related Issues, in particular in the Clean Air for Europe (CAFE) Programme. Volume 2: Health Impact Assessment. AEA Technology Environment, 2005.